中华实验外科杂志
中華實驗外科雜誌
중화실험외과잡지
CHINESE JOURNAL OF EXPERIMENTAL SURGERY
2014年
9期
2012-2014
,共3页
朱永云%陈创%谢闵%孙金中%赵迎春%孙圣荣
硃永雲%陳創%謝閔%孫金中%趙迎春%孫聖榮
주영운%진창%사민%손금중%조영춘%손골영
乳腺癌%量子点标记分子探针%趋化因子5%基质金属蛋白酶-9
乳腺癌%量子點標記分子探針%趨化因子5%基質金屬蛋白酶-9
유선암%양자점표기분자탐침%추화인자5%기질금속단백매-9
Breast cancer%Quantum dots bioprobes%Chemokine ligand 5%Matrix metalloproteinasec-9
目的 探讨CC类趋化因子5(CCL5)和基质金属蛋白酶(MMP)-9量子点定量信息对预测乳腺癌预后的价值.方法 利用量子点标记分子探针成像技术检测214例浸润性乳腺癌患者CCL5和MMP-9的表达,获得量子点评分(QDS),分析定量参数与3年预后的关系.结果 淋巴结阴性、阳性组CCL5 QDS为36.952±3.070、74.822±3.582,Lunminal A、Lunminal B、人类表皮生长因子受体(HER)-2阳性、三阴性组CCL5 QDS为39.134±3.709、70.911±4.984、59.260±5.785、61.316±9.212,CCL5表达差异有统计学意义(P＜0.01);淋巴结阴性、阳性组MMP-9 QDS为18.912±1.356、39.459±2.083,MMP-9表达差异有统计学意义(P＜0.01);CCL5 QDS与3年无病生存(3-DFS)呈负相关(r=-0.329,P＜0.01),MMP-9 QDS与3-DFS呈负相关(r=-0.346,P＜0.01);MMP-9是乳腺癌的独立预后因素[P＜0.01,曲线下面积(AUC) [95％可信区间(CI):3.489(1.736 ～7.011)].结论 量子点标记分子探针技术能简便准确地获取乳腺癌中CCL5和MMP-9定量信息,提示乳腺癌在CCL5和MMP-9表达上的异质性.
目的 探討CC類趨化因子5(CCL5)和基質金屬蛋白酶(MMP)-9量子點定量信息對預測乳腺癌預後的價值.方法 利用量子點標記分子探針成像技術檢測214例浸潤性乳腺癌患者CCL5和MMP-9的錶達,穫得量子點評分(QDS),分析定量參數與3年預後的關繫.結果 淋巴結陰性、暘性組CCL5 QDS為36.952±3.070、74.822±3.582,Lunminal A、Lunminal B、人類錶皮生長因子受體(HER)-2暘性、三陰性組CCL5 QDS為39.134±3.709、70.911±4.984、59.260±5.785、61.316±9.212,CCL5錶達差異有統計學意義(P＜0.01);淋巴結陰性、暘性組MMP-9 QDS為18.912±1.356、39.459±2.083,MMP-9錶達差異有統計學意義(P＜0.01);CCL5 QDS與3年無病生存(3-DFS)呈負相關(r=-0.329,P＜0.01),MMP-9 QDS與3-DFS呈負相關(r=-0.346,P＜0.01);MMP-9是乳腺癌的獨立預後因素[P＜0.01,麯線下麵積(AUC) [95％可信區間(CI):3.489(1.736 ～7.011)].結論 量子點標記分子探針技術能簡便準確地穫取乳腺癌中CCL5和MMP-9定量信息,提示乳腺癌在CCL5和MMP-9錶達上的異質性.
목적 탐토CC류추화인자5(CCL5)화기질금속단백매(MMP)-9양자점정량신식대예측유선암예후적개치.방법 이용양자점표기분자탐침성상기술검측214례침윤성유선암환자CCL5화MMP-9적표체,획득양자점평분(QDS),분석정량삼수여3년예후적관계.결과 림파결음성、양성조CCL5 QDS위36.952±3.070、74.822±3.582,Lunminal A、Lunminal B、인류표피생장인자수체(HER)-2양성、삼음성조CCL5 QDS위39.134±3.709、70.911±4.984、59.260±5.785、61.316±9.212,CCL5표체차이유통계학의의(P＜0.01);림파결음성、양성조MMP-9 QDS위18.912±1.356、39.459±2.083,MMP-9표체차이유통계학의의(P＜0.01);CCL5 QDS여3년무병생존(3-DFS)정부상관(r=-0.329,P＜0.01),MMP-9 QDS여3-DFS정부상관(r=-0.346,P＜0.01);MMP-9시유선암적독립예후인소[P＜0.01,곡선하면적(AUC) [95％가신구간(CI):3.489(1.736 ～7.011)].결론 양자점표기분자탐침기술능간편준학지획취유선암중CCL5화MMP-9정량신식,제시유선암재CCL5화MMP-9표체상적이질성.
Objective To explore the values for BC prediction in combination with CC chemokine ligand 5 (CCL5) and matrix metalloproteinasec (MMP)-9.Methods The quantitative and accurate determination of CCL5 and MMP-9 of 214 invasive BC tissue were acquired by QD-based immunohistochemistry (QD-IHC) and Wuda imaging analysis system.The relationships of quantitative CCL5 and MMP-9 determination with 3-year disease free survival (3-DFS) were investigated.Results CCL5 QDS of lymph node (-) group and lymph node (±) group was 36.952 ± 3.070 and 74.822 ± 3.582.CCL5 QDS of Lunminal A,Lunminal B,human epidermal growth factor receptor (HER-2) over-expression and triplenegative was 39.134 ±3.709,70.911 ±4.984,59.260 ±5.785,61.316 ±9.212.CCL5 QDS was correlated with lymph node metastasis and molecular sub-type (P ＜ 0.01).MMP-9 QDS of lymph node (-) group and lymph node (±) group was 18.912 ± 1.356,39.459 ±2.083.MMP-9 QDS was correlated with lymph node metastasis (P ＜ 0.01).There was a negative relationship between the expression of CCL5 (r =-0.329,P ＜ 0.01) and MMP-9 (r =-0.346,P ＜ 0.01) with 3-DFS.On multivariate analysis MMP-9 was indeed an independent predictor of 3-DFS (P ＜ 0.01,area under curve (AUC) [95％ confidence interval (CI):3.489 (1.736-7.011)].Conclusion QD-IHC nanotechnology can assess CCL5 and MMP-9 expression in BC accurately and quantitatively,reveal BC heterogeneity.
